Literature DB >> 20530926

Two cases of inflammatory bowel disease diagnosed in the course of primary biliary cirrhosis.

Osamu Arai1, Hiroshi Ikeda, Hirokazu Mouri, Kenji Notohara, Kazuhiro Matsueda.   

Abstract

Inflammatory bowel disease (IBD), especially ulcerative colitis (UC), sometimes accompanies with primary sclerosing cirrhosis (PSC). Primary biliary cirrhosis (PBC) is also a chronic liver disease, but is attributed to an unknown immune abnormality. PBC frequently accompanies various autoimmune diseases, but rarely IBD. We report 2 rare cases of IBD which developed in the course of treatment for PBC. A 64-year-old man had blood in his stool 17 months after he was given a diagnosis of PBC. Colonoscopy revealed erosion and disappearance of the vascular network pattern in the rectum. UC (rectal type) was diagnosed and he received mesalazine, and following which his symptoms improved. A 40-year-old woman developed diarrhea, fever and arthralgia while receiving treatment for PBC. Colonoscopy revealed ileal erosion, a longitudinal ulcer in the ascending colon but only mild rectal inflammation. These findings were atypical of UC, and we therefore diagnosed indeterminate colitis. Her symptoms disappeared as a result of the administration of mesalazine.

Entities:  

Mesh:

Year:  2010        PMID: 20530926

Source DB:  PubMed          Journal:  Nihon Shokakibyo Gakkai Zasshi        ISSN: 0446-6586


  3 in total

1.  Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments.

Authors:  Palak J Trivedi; Sue Cullen
Journal:  Hepatol Int       Date:  2012-03-20       Impact factor: 6.047

2.  Primary biliary cirrhosis presenting with gastritis, hyperlipidemia and marked weight loss.

Authors:  Moushumi Lodh; Debkanta Pradhan; Abhishek Mukherjee
Journal:  Indian J Clin Biochem       Date:  2011-07-14

Review 3.  Mechanisms of tissue injury in autoimmune liver diseases.

Authors:  Evaggelia Liaskou; Gideon M Hirschfield; M Eric Gershwin
Journal:  Semin Immunopathol       Date:  2014-08-01       Impact factor: 9.623

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.